يعرض 11 - 20 نتائج من 156 نتيجة بحث عن '"Willeke A M, Blokx"', وقت الاستعلام: 0.85s تنقيح النتائج
  1. 11
  2. 12
  3. 13

    المساهمون: Faculteit Medische Wetenschappen/UMCG, Guided Treatment in Optimal Selected Cancer Patients (GUTS), Health Technology Assessment (HTA), Erasmus MC other, Medical Oncology, Surgery, Internal medicine, Medical oncology, AII - Cancer immunology, CCA - Cancer Treatment and quality of life, CCA - Cancer biology and immunology, Obstetrics and gynaecology, Amsterdam Reproduction & Development (AR&D)

    المصدر: Annals of Surgical Oncology, 30, 587-588
    Annals of surgical oncology, 30(1), 587-588. SPRINGER
    Annals of Surgical Oncology, 30, 1, pp. 587-588
    Annals of Surgical Oncology, 30, 587-588. SPRINGER
    Annals of Surgical Oncology, 30(1), 587-588. Springer New York
    Blankenstein, S A, Bonenkamp, J J, Aarts, M J B, van den Berkmortel, F W P J, Blank, C U, Blokx, W A M, Boers-Sonderen, M J, van den Eertwegh, A J M, Franken, M G, de Groot, J W B, Haanen, J B A G, Hospers, G A P, Kapiteijn, E W, van Not, O J, Piersma, D, van Rijn, R S, Suijkerbuijk, K P M, van der Veldt, A A M, Vreugdenhil, G, Westgeest, H M, Wouters, M W J M & van Akkooi, A C J 2023, ' ASO Visual Abstract : Is a History of Optimal Staging by SLNB in the Era Prior to Adjuvant Therapy Associated with Improved Outcome Once Melanoma Patients have Progressed to Advanced Disease? ', Annals of Surgical Oncology, vol. 30, no. 1, pp. 587-588 . https://doi.org/10.1245/s10434-022-12719-2Test

    وصف الملف: application/pdf

  4. 14
  5. 15

    المساهمون: RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, Interne Geneeskunde, MUMC+: MA Medische Oncologie (9), Medical Oncology, Radiology & Nuclear Medicine, Guided Treatment in Optimal Selected Cancer Patients (GUTS), Internal medicine, Medical oncology, AII - Cancer immunology, CCA - Cancer Treatment and quality of life, Obstetrics and gynaecology, Amsterdam Reproduction & Development (AR&D)

    المصدر: International Journal of Cancer, 150(5), 816-824. Wiley
    van Not, O J, van Breeschoten, J, van den Eertwegh, A J M, Hilarius, D L, de Meza, M M, Haanen, J B, Blank, C U, Aarts, M J B, van den Berkmortel, F W P J, de Groot, J W B, Hospers, G A P, Ismail, R K, Kapiteijn, E, Piersma, D, van Rijn, R S, Stevense-den Boer, M A M, van der Veldt, A A M, Vreugdenhil, G, Boers-Sonderen, M J, Blokx, W A M, Suijkerbuijk, K P M & Wouters, M W J M 2022, ' The unfavorable effects of COVID-19 on Dutch advanced melanoma care ', International Journal of Cancer, vol. 150, no. 5, pp. 816-824 . https://doi.org/10.1002/ijc.33833Test
    International Journal of Cancer, 150, 816-824
    International Journal of Cancer, 150, 5, pp. 816-824
    International Journal of Cancer, 150(5), 816-824. Wiley-Liss Inc.
    International Journal of Cancer, 150(5), 816-824. WILEY
    International Journal of Cancer

    وصف الملف: application/pdf

  6. 16

    المساهمون: Medical Oncology, Radiology & Nuclear Medicine, Internal medicine, Medical oncology, AII - Cancer immunology, CCA - Cancer Treatment and quality of life, RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, Interne Geneeskunde, MUMC+: MA Medische Oncologie (9), Guided Treatment in Optimal Selected Cancer Patients (GUTS)

    المصدر: JAMA Oncology. AMER MEDICAL ASSOC
    JAMA Oncology
    JAMA Oncology, 8(12), 1794-1801. American Medical Association
    van Not, O J, Verheijden, R J, van den Eertwegh, A J M, Haanen, J B A G, Aarts, M J B, van den Berkmortel, F W P J, Blank, C U, Boers-Sonderen, M J, de Groot, J-W B, Hospers, G A P, Kamphuis, A M, Kapiteijn, E, May, A M, de Meza, M M, Piersma, D, van Rijn, R, Stevense-den Boer, M A, van der Veldt, A A M, Vreugdenhil, G, Blokx, W A M, Wouters, M J M & Suijkerbuijk, K P M 2022, ' Association of Immune-Related Adverse Event Management with Survival in Patients with Advanced Melanoma ', JAMA Oncology, vol. 8, no. 12, pp. 1794-1801 . https://doi.org/10.1001/jamaoncol.2022.5041Test
    JAMA oncology, 8(12), 1794-1801. AMER MEDICAL ASSOC
    Jama Oncology, 8, 12, pp. 1794-1801
    Jama Oncology, 8, 1794-1801

    وصف الملف: application/pdf

  7. 17
  8. 18
  9. 19
  10. 20

    المساهمون: VU University medical center, Obstetrics and gynaecology, Internal medicine, AII - Cancer immunology, CCA - Cancer Treatment and quality of life, Radiology & Nuclear Medicine, RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, Interne Geneeskunde, MUMC+: MA Medische Oncologie (9)

    المصدر: British Journal of Cancer
    British Journal of Cancer, 124(7), 1222-1230. Nature Publishing Group
    British Journal of Cancer, 124, 7, pp. 1222-1230
    British Journal of Cancer, 124, 1222-1230
    van Breeschoten, J, Wouters, M W J M, Hilarius, D L, Haanen, J B, Blank, C U, Aarts, M J B, van den Berkmortel, F W P J, de Groot, J-W B, Hospers, G A P, Kapiteijn, E, Piersma, D, van Rijn, R S, Suijkerbuijk, K P M, Blokx, W A M, Tije, B-J J T, Veldt, A A M V D, Vreugdenhil, A, Boers-Sonderen, M J & van den Eertwegh, A J M 2021, ' First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis ', British Journal of Cancer, vol. 124, no. 7, pp. 1222-1230 . https://doi.org/10.1038/s41416-020-01229-1Test
    British Journal of Cancer, 124(7), 1222-1230. SPRINGERNATURE

    وصف الملف: application/pdf